Sudarshan Pharma Lines Up 20 Million Dollar FCCB To Fuel Global Growth

Sudarshan Pharma Industries has approved an international fundraise of up to 20 million US dollars via senior unsecured foreign currency convertible bonds due 2029, strengthening its capital base to pursue expansion in specialty pharma and chemicals.

Sudarshan Pharma Industries has approved an international fundraise of up to 20 million US dollars via senior unsecured foreign currency convertible bonds due 2029, strengthening its capital base to pursue expansion in specialty pharma and chemicals.

The approval follows earlier shareholder and stock exchange clearances for an FCCB programme. The Mumbai-headquartered company will now access offshore capital markets, with a defined coupon, conversion framework and clear timelines, offering investors a structured way to participate in its growth while creating a future equity option.

FCCB Structure And Strategic Intent

The board has cleared issuance of up to 20 million US dollars of 8 percent senior unsecured foreign currency convertible bonds, to be placed in one or more tranches through an international offering. The FCCBs will have a tenure of three years and two months from the date they are fully paid up, maturing in 2029, and will be backed by a detailed offering circular.

Conversion Economics And Potential Dilution

For conversion, the company has fixed the relevant date as 15 May 2026, with a regulatory floor price of 30.19 rupees per share under applicable FCCB guidelines. At the full issue size, this equates to around 191.86 crore rupees and an estimated 6.36 crore equity shares of face value 1 rupee each on full conversion, implying meaningful but calibrated dilution aligned with growth capital needs.

Timeline, Governance And Execution Roadmap

The FCCB issue opens on 18 May 2026, with allotment to be completed within 60 days from the issue closing date, subject to customary conditions. Chairman and Managing Director Hemal Vasantrai Mehta and Joint Managing Director Sachin Vasantrai Mehta have been authorised to execute all related documents, negotiate final terms and make amendments as needed to ensure smooth completion of the foreign currency bond issuance.

Key highlights  

• Issue size: Up to 20 million US dollars in FCCBs  
• Instrument: 8 percent senior unsecured foreign currency convertible bonds due 2029  
• Type of issuance: International offering in one or more tranches  
• Relevant date for pricing: 15 May 2026 under FCCB guidelines  
• Regulatory floor price: 30.19 rupees per equity share for conversion  
• Indicative rupee value: Around 191.86 crore rupees at 1 dollar = 95.93 rupees  
• Estimated equity on full conversion: Approximately 6,35,50,845 shares of face value 1 rupee each  
• Issue opening and allotment: Book opens 18 May 2026; allotment within 60 days of issue close  

Sources: Company disclosure to stock exchange dated 15 May 2026, FCCB issuance approval and accompanying annexures.